Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

NCT06807606 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Drugs Cyclophosphamide
DRUG: Fludarabine
DRUG: Thiotepa
DRUG: Tacrolimus
DRUG: Mycophenolate mofetil

Sponsor

M.D. Anderson Cancer Center